TESARO Inc (NASDAQ:TSRO) major shareholder Enterprise Associates 13 L. New purchased 54,642 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were acquired at an average price of $55.56 per share, for a total transaction of $3,035,909.52. Following the purchase, the insider now directly owns 252 shares of the company’s stock, valued at approximately $14,001.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
TESARO Inc (TSRO) traded down $1.91 on Wednesday, reaching $62.69. The company’s stock had a trading volume of 818,816 shares, compared to its average volume of 1,120,000. TESARO Inc has a 52 week low of $52.20 and a 52 week high of $171.80. The firm has a market capitalization of $3,410.00, a price-to-earnings ratio of -6.83 and a beta of 1.40. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74.
TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.96). TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. The company had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $51.78 million. sell-side analysts predict that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
TSRO has been the topic of a number of recent research reports. Citigroup reiterated a “buy” rating and issued a $135.00 target price (down previously from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Morgan Stanley lowered their price objective on TESARO from $165.00 to $156.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 16th. HC Wainwright restated a “buy” rating and issued a $158.00 price objective on shares of TESARO in a research report on Friday, January 12th. Cowen reduced their target price on TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a research note on Tuesday, January 2nd. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $150.00 target price (down from $190.00) on shares of TESARO in a research note on Thursday, January 18th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $133.39.
TRADEMARK VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/03/14/tesaro-inc-tsro-major-shareholder-purchases-3035909-52-in-stock.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.